前沿论文｜CELL INTELLIGENCE

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

PubMed 2026/09/19 发表Hum PatholQ2 · IF 3（JCR 2025）

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

PubMed 2026/09/08 发表Blood AdvQ1 · IF 7.7（JCR 2025）

Primary Plasma Cell Leukemia.

PubMed 2026/08/31 发表Am J HematolQ1 · IF 9.4（JCR 2025）

B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.

PubMed 2026/08/19 发表Cancers (Basel)Q2 · IF 4.8（JCR 2025）

How I treat plasma cell leukemia.

PubMed 2026/07/23 发表BloodQ1 · IF 23.9（JCR 2025）

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

PubMed 2026/06/03 发表Am J HematolQ1 · IF 9.4（JCR 2025）

Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma.

PubMed 2026/05/22 发表Leuk LymphomaQ3 · IF 2.1（JCR 2025）

Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies.

PubMed 2026/05/21 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1（JCR 2025）

在接受靶向 CD38 和 BCMA 药物的 MM 患者中，低水平 CMV 检出较为常见，但病毒血症通常具有自限性，在我们的研究队列中，尽管 CMV 检出率相对较高，却没有出现有症状的 CMV 感染。

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

PubMed 2026/05/16 发表Int ImmunopharmacolQ1 · IF 5.6（JCR 2025）

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure.

PubMed 2026/04/06 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1（JCR 2025）

前沿论文 58